

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES
OF THE RED HERRING PROSPECTUS**



This is an Abridged Prospectus containing salient features of the Red Herring Prospectus dated June 11, 2025 (the “RHP”). You are encouraged to read greater details available in the RHP, which is available on the website of the Stock Exchange (https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer), the Company (<https://influxhealthtech.com/investor-relations/>) and the Book Running Lead Manager (“BRLM”) (<https://rarever.in/transactions>). Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP.

THIS ABRIDGED PROSPECTUS CONSISTS OF 10 PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.



INFLUX HEALTHTECH LIMITED

Corporate Identification Number: U24299MH2020PLC346825 | **Date of Incorporation:** September 28, 2020

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 Maharashtra, India	-	Mr. Atul Kumar Ashok Kumar Shukla (Company Secretary & Compliance Officer)	Email: cs@influxhealthtech.com Tel: +91 7045997809	www.influxhealthtech.com

OUR PROMOTERS: Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala

Details of Offer to Public								
Type of Offer	Fresh Offer Size	OFS Size	Total Offer Size	Offer Under	Share Reservation			
					Market Maker	QIB	NII	RII
Fresh Offer and Offer for Sale.	Up to 50,00,400 Equity Shares aggregating to ₹ [●] Lakhs	Up to 11,00,400 Equity Shares aggregating to ₹ [●] Lakhs	₹ 61,00,800 Lakhs	The Offer is being made pursuant to Regulation 229(2) & 253(1) of Chapter IX of SEBI ICDR Regulations, 2018	3,06,000 Equity Shares	Not more than 28,95,600 Equity Shares	Not less than 8,70,000 Equity Shares	Not less than 20,29,200 Equity Shares

These equity shares are proposed to be listed on NSE Emerge (i.e. SME platform of NSE).

OFS: Offer for Sale

Details of OFS by Promoter(s)/ Promoter Group/ Other Selling Shareholders (upto a maximum of 10 selling shareholders)			
Name	Type	No of Shares offered/ Amount in ₹	Weighted Average Cost of Acquisition Per Equity Share (₹)

Mr. Munir Abdul Ganee Chandniwala	Promoter	Up to 11,00,400 Equity Shares aggregating upto ₹ [●] Lakhs	Nil
-----------------------------------	----------	--	-----

PRICE, MINIMUM BID LOT & INDICATIVE TIMELINES			
Price Band *	₹ 91 to ₹ 96	Minimum bid lot size	1200 Equity Shares
Anchor Investor Bidding Date#	June 17, 2025	Initiation of Unblocking of Funds/refunds	June 24, 2025
Bid/Offer Opens On	June 18, 2025	Credit of Equity Shares to demat accounts of Allotees	June 24, 2025
Bid/Offer Closes On	June 20, 2025	Commencement of Trading of Equity Shares on the Stock Exchanges	June 25, 2025
Finalisation of Basis of Allotment	June 23, 2025		

* For details of price band and basis of issue price, please refer to price band advertisement and page 134 of RHP.

#Our Company, in consultation with the BRLM, may consider participation by Anchor Investors, in accordance with the SEBI (ICDR) Regulations.

Details of WACA of all shares transacted over the trailing eighteen months from the date of RHP			
Period	Weighted Average Cost of Acquisition (in ₹)	Upper End of the Price Band is 'X' times the WACA (in ₹ 96)	Range of acquisition price Lowest Price-Highest Price (in ₹ 91)
WACA of Primary issuance	Negligible	Nil	Nil
WACA of Secondary transactions	Negligible	Nil	Nil


RISKS IN RELATION TO THE FIRST OFFER
The face value of the Equity Shares is ₹10. The Floor Price, Cap Price and Offer Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under 'Basis for Offer Price' on page 134 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISKS
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares offered in the Offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section 'Risk Factors' beginning on page 38 of Red Herring Prospectus.
PROCEDURE
You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, Registrar to the Offer, Share Transfer Agents, Depository Participants, Stockbrokers, Underwriters, Bankers to the Offer, Investors' Associations or Self Certified Syndicate Banks.
If you wish to know about processes and procedures applicable to this Offer, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM or download it from the website of the Stock Exchange i.e. www.nseindia.com and the BRLM i.e. https://rarever.in/transactions

PRICE INFORMATION OF BRLM: RAREVER FINANCIAL ADVISORS PRIVATE LIMITED							
Issue Name	Issue Size (in Cr.)	Issue Price	Listing Date	Opening Price on Listing Date	% Change in closing price (% change in closing benchmark)		
					30 th calendar day from listing	90 th calendar day from listing	180 th calendar day from listing
NIL							

Source: www.nseindia.com

SUMMARY STATEMENT OF DISCLOSURE														
FY	Total No. of IPOs	Total Funds Raised (₹ in Cr.)	Nos. of IPO trading at discount as on 30 th calendar day from listing date			Nos. of IPO trading at premium as on 30 th calendar day from listing date			Nos. of IPO trading at discount as on 180 th calendar day from listing date			Nos. of IPO trading at premium as on 180 th calendar day from listing date		
			Over 50 %	Between n 25-50%	Less than 25 %	Over 50 %	Between n 25-50%	Less than 25 %	Over 50 %	Between 25-50%	Less than 25 %	Over 50 %	Between 25-50%	Less than 25 %
			NIL											

Source: www.nseindia.com

Name of BRLM & Contact details	 <p>RAREVER FINANCIAL ADVISORS PRIVATE LIMITED 807, Iconic Shyamal, Shyamal Cross Road, 132 Ring Road, Satellite, Manekbag, Ahmedabad, Gujarat, 380015 India Tel: 079-4925 8260 / +91 99981 23745 Email: ipo.influxhealth@rarever.in Investor Grievances Email id- IG@rarever.in Website: www.rarever.in SEBI Registration: INM000013217 Contact Person: Mr. Richi Shah / Mr. Prerak Thakkar</p>
Name of Syndicate Members	Not Applicable
Details of the Market Maker	<p>R.K. STOCKHOLDING PRIVATE LIMITED RO Address: A-7, Block B-1, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi – 110044, New Delhi, India Telephone: +91 98100 46444 Email: navdeep@rkfml.com Contact Person: Navdeep Varshneya SEBI Registration Number: INZ000211932 Market Maker Registration Number: 12310</p>
Name of Registrar to the Issue and contact details (telephone and email id)	 <p>MAASHITLA SECURITIES PRIVATE LIMITED 451, Krishna Apra Business Square Netaji Subhash Place, Pitampura, Northwest, New Delhi, Delhi - 110034, India Tel No.: +91-11-47581432 E-mail: ipo@maashitla.com Investor Grievances Email Id – investor.ipo@maashitla.com Website: www.maashitla.com</p>

	SEBI Registration No.: INR000004370 Contact Person: Mr. Mukul Agrawal
Name of Statutory/ Peer Review Auditor	M/s. V.B. Goel & Co. Chartered Accountants Firm Registration No.: 115906W Address: 6 th Floor, Simba Tower, Vishveshwar Nagar, Near Virwani Industrial Industrial Estate, Goregaon (East), Mumbai- 400063, Maharashtra, India Tel: 022- 35174220/ 35174263/ 46030191 Email: info@vbgco.com Contact Person: Mr. Vikas Goel Peer Review No.: 015192
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture trustee, if any	Not Applicable
Self-Certified Syndicate Banks	The list of banks is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 which is updated from time to time
Non-Syndicate Registered Brokers	The list of Registered Brokers is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes which is updated from time to time
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes

OUR PROMOTERS			
Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1.	Mr. Munir Abdul Ganee Chandniwala	Individual	<p>Experience: Mr. Munir Abdul Ganee Chandniwala, is the Founder & Managing Director of the Company. He has experience of approx. 22 years in the industry of Nutraceutical, Cosmetics, Ayurvedic and Homecare. He has managed and controlled the affairs of Influx Healthcare, a sole proprietorship engaged in Third Party Manufacturing in Nutraceuticals, Cosmetics and Ayurvedic Products, since 2002. He has been successful entrepreneur in the field of Third-Party Manufacturing, Contract Development and Manufacturing since 2002.</p> <p>Educational Qualification: Postgraduate in Management and Business Administration, Bachelor of Pharmacy and Doctor of Philosophy programme.</p>
2.	Mrs. Shirin Munir Ahmed Chandniwala	Individual	<p>Experience: Mrs. Shirin Munir Ahmed Chandniwala, is the founder and Whole-Time Director of the Company. Mrs. Shirin Chandniwala is well versed with financial management data analysis and budget oversight. With more than 12 years of experience in the field of trading of packaging materials; Mrs. Shirin Chandniwala has been an integral part of the Company</p>

			<p>since inception. She is well qualified to supervise the overall financial Development at influx. She has the experience of third-party manufacturing solutions in the fields of Nutraceuticals, Cosmetics, Ayurveda, Petcare and Homecare. Her practical knowledge and hands-on experience have been vital in managing complex business situations and contributing to the company's growth. Since 2012, she is the partner of Shinaf Enterprise, a partnership firm engaged in the trading of packaging materials.</p> <p>Educational Qualification: Bachelor and Master of Commerce from Hemchandracharya North Gujrat University</p>
3.	Mr. Abdul Ganee Abdul Rasul Chandniwala	Individual	<p>Experience: Abdul Ganee Abdul Rasul Chandniwala, is the Non-executive Director of the company. Mr. Abdul Ganee Abdul Rasul Chandniwala has been an integral part of Influx with his approximately 21 years of experience in the pharmaceutical industry. In these 18 years of Experience, Mr. Chandniwala has been actively involved in assisting his son for the promotion of Influx Healthcare, which is involved on third-party manufacturing of nutraceuticals, cosmetics, and Ayurvedic products, where he has assisted his son in its growth and development.</p> <p>Educational Qualification: Diploma of licentiate of Court of examiners of Homoeopathic and Biochemic system of Medicine and Certificate Course in modern Pharmacology, Maharashtra University of Health Science, Nashik.</p>

BUSINESS OVERVIEW AND STRATEGY

<p>Company Overview: Influx Healthtech Limited is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Our Company was originally incorporated on September 28, 2020 as a Private Limited Company as "Influx Healthtech Private Limited" vide Registration No. 346825 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Central Registration Centre. Pursuant to a special resolution passed by the shareholders at their Extra Ordinary General Meeting held on May 09, 2022, our company was converted from a Private Limited Company to Public Limited Company. Consequently, the name of our Company was changed to "Influx Healthtech Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on May 23, 2022, by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U24299MH2020PLC346825.</p>				
<p>Product/Service Offering: For details, please refer to page no 167 of the Red Herring Prospectus.</p>				
<p>Revenue segmentation by product/service offering: For details, please refer to page no 171 of the Red Herring Prospectus.</p>				
<p>Geographies Served & Revenue segmentation by geographies: For details, please refer to page no 191 of the Red Herring Prospectus.</p>				
<p>Key Performance Indicators: For details, please refer to "Basis for Issue Price" on page no. 138 of the Red Herring Prospectus.</p>				
<p>Client Profile or Industries Served: For details, please refer to page no 173 of the Red Herring Prospectus.</p>				
<p>Revenue segmentation in terms of top 5/10 clients or Industries: For details, please refer to page no 192 of the Red Herring Prospectus.</p>				
<p>Intellectual Property, if any: For details, please refer to page no 196 of the Red Herring Prospectus</p>				
<p>Market Share: Not ascertainable</p>				
<p>Manufacturing plant, if any: For details, please refer to page no 201 of the Red Herring Prospectus</p>				
<p>Employee Strength: As on March 31, 2025, we have total 179 employees.</p>				

BOARD OF DIRECTORS

Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)	Experience & Educational Qualification	Other Directorships

1.	Mr. Munir Abdul Ganee Chandniwala	Chairman and Managing Director	<p>Experience: Mr. Munir Abdul Ganee Chandniwala, is the Founder & Managing Director of the Company. He has experience of approx. 22 years in the industry of Nutraceutical, Cosmetics, Ayurvedic and Homecare. He has managed and controlled the affairs of Influx Healthcare, a sole proprietorship engaged in Third Party Manufacturing in Nutraceuticals, Cosmetics and Ayurvedic Products, since 2002. He has been successful entrepreneur in the field of Third-Party Manufacturing, Contract Development and Manufacturing since 2002.</p> <p>Educational Qualification: Post Graduate in Management and Business Administration, Bachelor of Pharmacy and Doctor of Philosophy programme.</p>	<ul style="list-style-type: none"> • Trusan Printpack Private Limited • ESLP Digital LLP • Influx Foundation (Not-for-Profit Organisation)
2.	Mrs. Shirin Munir Ahmed Chandniwala	Whole-time Director	<p>Experience: Mrs. Shirin Munir Ahmed Chandniwala, is the founder and Whole-Time Director of the Company. Mrs. Shirin Chandniwala is well versed with financial management data analysis and budget oversight. With more than 12 years of experience in the field of trading of packaging materials; Mrs. Shirin Chandniwala has been an integral part of the Company since inception. She is well qualified to supervise the overall financial Development at influx. She has the experience of third-party manufacturing solutions in the fields of Nutraceuticals, Cosmetics, Ayurveda, Petcare and Homecare. Her practical knowledge and hands-on experience have been vital in managing complex business situations and contributing to the company's growth. Since 2012, she is the partner of Shinaf Enterprise, a partnership firm engaged in the trading of packaging materials.</p> <p>Educational Qualification: Bachelor and Master of Commerce from Hemchandracharya North Gujrat University</p>	<ul style="list-style-type: none"> • ESLP Digital LLP • Influx Foundation (Not-for-Profit Organisation)

3.	Mr. Abdul Ganee Abdul Rasul Chandniwala	Non-Executive Director	<p>Experience: Abdul Ganee Abdul Rasul Chandniwala, is the Non-executive Director of the company. Mr. Abdul Ganee Abdul Rasul Chandniwala has been an integral part of Influx with his approximately 21 years of experience in the pharmaceutical industry. In these 18 years of Experience, Mr. Chandniwala has been actively involved in assisting his son for the promotion of Influx Healthcare, which is involved on third-party manufacturing of nutraceuticals, cosmetics, and Ayurvedic products, where he has assisted his son in its growth and development.</p> <p>Educational Qualification: Diploma of licentiate of Court of examiners of Homoeopathic and Biochemic system of Medicine and Certificate Course in modern Pharmacology, Maharashtra University of Health Science, Nashik.</p>	Nil
4.	Mr. Vipul Balubhai Patel	Independent Director	<p>Experience: Mr. Vipul Balubhai Patel, is the Non- Executive Independent Director on the Board of Influx Healthtech Limited. He is the Founder Director of Sunflower Laboratory & Diagnostic Center in Mumbai since 1998. He has 26 years of experience in the healthcare industry. Under his direction, the company achieves consistent growth, driven by a professional team dedicated to excellence.</p> <p>Education Qualification: M.D (Pathology), Maharashtra medical council and M.B.B.S, Maharashtra medical council.</p>	<ul style="list-style-type: none"> • Malad Gymkhana Limited • Sunflower Laboratory Private Limited
5.	Mr. Ashok Kumar Jain	Independent Director	<p>Experience: Mr. Ashok Kumar Jain, is the Non- Executive Independent Director on the Board of Influx Healthtech Limited. He has an experience of over 30 years in the field of financial management, strategic planning and market analysis. He has a strong understanding of market dynamics and trends, allowing him to guide organizations in achieving and surpassing their market value</p>	<ul style="list-style-type: none"> • Silicon Rentals Solutions Limited

			objectives. He brings a wealth of experience to the board of directors of the Company. He actively contributes to shaping the company's financial strategies and long-term planning.	
			Education Qualification: Chartered Accountant	

OBJECT OF THE OFFER

Our Company proposes to utilize the funds which are being raised through this Offer (“**Net Proceeds**”) towards the following objects:

1. Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division;
2. Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division;
3. Purchase of Machineries for Homecare and Cosmetic Division; and
4. General Corporate Purposes.

(1, 2 and 3 shall collectively referred to as ‘Proposed Expansion’ and 1 to 4 shall collectively referred to as ‘Objects’)

Utilization of Net Proceeds:

	Total Estimated Cost	Amount already deployed as on June 10, 2025 ⁽¹⁾	Amount which will be financed from Net Proceeds	Estimated Utilization of Net Proceeds	
				Fiscal 2026	Fiscal 2027
Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division	2,260.11	11.00	2,249.11	1,249.00	1,000.11
Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division	1,158.58	10.00	1,148.58	600.00	548.58
Purchase of Machineries for Homecare and Cosmetic Division	275.65	-	275.65	250.00	25.65
General corporate purposes ⁽²⁾⁽³⁾	[•]	-	[•]	[•]	-
Total	[•]	[•]	[•]	[•]	[•]

(1) As of March 31, 2025 our company has deployed ₹ 21 Lakhs from Internal Accruals, toward purchase of land for Nutraceutical and Veterinary food division manufacturing unit as certified by statutory auditor, M/s V.B. Goel & Co., Chartered Accountants vide certificate dated June 10, 2025.

(2) To be finalised upon determination of Offer Price and updated in the Prospectus prior to filing with the RoC.

(3) The amount to be utilized for general corporate purposes alone shall not exceed 25% of the Gross Proceeds.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years. - Not Applicable

Name of monitoring agency, if any: - Not Applicable

Terms of Issuance of Convertible Security, if any: - Not Applicable

Shareholding Pattern:

Sr. No.	Particulars	Pre Issue number of shares	% Holding of Pre issue
1.	Promoter and Promoter Group	1,81,23,864	99.86%
2.	Public	26,136	0.14%

Total	1,81,50,000	100.00%
--------------	--------------------	----------------

Number/amount of equity shares proposed to be sold by selling shareholders, if any: Up to 11,00,400 Equity Shares

RESTATED FINANCIALS STATEMENT

(Amt. in ₹ Lakhs)

Particulars	As at the Financial Year ended		
	March 31, 2025	March 31, 2024	March 31, 2023
Total income from operations (Net)	10,485.36	9,996.51	7,605.65
Net Profit/(Loss) before tax and extraordinary items	1,787.91	1,493.28	973.63
Net Profit / (Loss) after tax and extraordinary items	1,336.60	1,112.80	719.63
Equity Share Capital	1,815.00	2.50	2.50
Reserves and Surplus	1,799.54	2,275.44	1,162.65
Net worth	3614.54	2277.94	1165.15
Basic & Diluted earnings per share (Rs.)	7.36	6.13	3.96
Return on net worth (%)	36.98%	48.85%	61.76%
Net asset value per share (Rs.)	19.91	9,111.77	4,660.59

INTERNAL RISK FACTOR

The below mentioned risks are top 5 risk factors as per the RHP.

1. Our Company is reliant on the demand from the nutraceutical industry for a significant portion of our revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.
2. Our existing manufacturing facility are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow our business in this particular region may have an adverse effect on our business, financial condition, results of operations, cash flows and future business prospects.
3. Our Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
4. We have historically derived, and may continue to derive, a significant portion of our supply from top 10 Suppliers. Also, Our Company has not entered into long-term agreements with these suppliers. In the event we are unable to procure adequate amounts of raw materials, at competitive prices our business, results of operations and financial condition may be adversely affected.
5. Too much Geographical concentration of our Business on specific location can impact our Business.

For further details on '**Risk Factors**' please refer page 38 of the RHP.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

1. Total number of outstanding litigations against the Company and the amount involved

Name	By/ Against	Civil	Criminal	Tax related	Actions by regulatory authorities	Other Pending Litigations	Amount Involved (₹ in lakhs)
Company	By	-	-	-	-	-	-
	Against	-	-	-	-	-	-
Promoter	By	-	-	-	-	-	-
	Against	-	-	-	-	-	-
Promoter Group	By	-	-	-	-	-	-
	Against	-	-	-	-	-	-

Name	By/ Against	Civil	Criminal	Tax related	Actions by regulatory authorities	Other Pending Litigations	Amount Involved (₹ in lakhs)
Group Companies/ Entities	By	-	-	-	-	-	-
	Against	-	-	-	-	-	-
Directors other than promoters	By	-	-	-	-	-	-
	Against	-	-	6	-	-	36.96

2. Brief details of top 5 material outstanding litigations against the Company and the amount involved:

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved (Rs. in millions)
NIL				

3. Regulatory action, if any – disciplinary action taken by SEBI or Stock Exchanges against the Promoters in last 5 financial years including outstanding action, if any - Nil

4. Brief details of outstanding criminal proceedings against the promoter - Nil

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY – NIL

DECLARATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 1956, the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 1956, the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.